1.57
3.09%
-0.05
Dopo l'orario di chiusura:
1.57
Spero Therapeutics Inc Borsa (SPRO) Ultime notizie
Spero Therapeutics to Participate in H.C. Wainwright Annual - GlobeNewswire
GlobeNewswire
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire Inc.
HC Wainwright Reaffirms Buy Rating for Spero Therapeutics (NASDAQ:SPRO) - MarketBeat
MarketBeat
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update - Yahoo Finance
Yahoo Finance
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Spero Therapeutics (SPRO) Set to Announce Earnings on Wednesday - Defense World
Defense World
Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years - Yahoo New Zealand News
Yahoo New Zealand News
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies UK
Yahoo Movies UK
Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy? - Yahoo News UK
Yahoo News UK
Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago - Yahoo Finance
Yahoo Finance
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday - MarketBeat
MarketBeat
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May ... - GlobeNewswire
GlobeNewswire
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
GlobeNewswire Inc.
Investors in Spero Therapeutics (NASDAQ:SPRO) from three years ago are still down 88%, even after 12% gain this past week - Simply Wall St
Simply Wall St
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Yahoo Finance
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Yahoo Finance
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value (NASDAQ:SPRO) - Seeking Alpha
Seeking Alpha
14 Cheap Penny Stocks to Buy According to Analysts - Insider Monkey
Insider Monkey
ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains - StockNews.com
StockNews.com
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Yahoo Finance
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024 - Yahoo Finance
Yahoo Finance
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
GlobeNewswire Inc.
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Zacks Investment Research
Zacks Investment Research
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27% - Simply Wall St
Simply Wall St
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
GlobeNewswire Inc.
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on ... - Yahoo Finance
Yahoo Finance
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
GlobeNewswire Inc.
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections - GlobeNewswire
GlobeNewswire
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
GlobeNewswire Inc.
Have Insiders Sold Spero Therapeutics Shares Recently? - Simply Wall St
Simply Wall St
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
JNJ: Top 4 Pharma Stocks on the Rise for Potential Gains - StockNews.com
StockNews.com
Spero Therapeutics Provides Corporate Update and 2024 Outlook
GlobeNewswire Inc.
Spero Therapeutics Provides Corporate Update and 2024 Outlook - GlobeNewswire
GlobeNewswire
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
GlobeNewswire Inc.
SPRO: 3 Pharma Stocks to Buy Before Year-End - StockNews.com
StockNews.com
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update - Yahoo Finance
Yahoo Finance
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer - GlobeNewswire
GlobeNewswire
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of ... - Yahoo Finance
Yahoo Finance
Spero Therapeutics: Multi-Asset Pipeline Could Outpace Tebipenem HBr Deal With GSK - Seeking Alpha
Seeking Alpha
PFE: 3 Pharma Stocks Every Investor Should Know - StockNews.com
StockNews.com
Spero CEO to step down; new CEO to turn focus toward lung disease antibiotic - Boston Business Journal - The Business Journals
The Business Journals
Spero Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
GlobeNewswire
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround - Yahoo New Zealand News
Yahoo New Zealand News
Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery ... - Business Wire
Business Wire
Capitalizzazione:
|
Volume (24 ore):